Clinicopathologic features and survival outcomes of ocular melanoma: a series of 31 cases from a tertiary university hospital
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: We aimed to determine the effect of clinicopathologic features on overall survival among Caucasian ocular melanoma patients in the Central Anatolia region of Turkey.Methods: This single-center study included conjunctival (n = 12) and uveal (n = 19) melanoma patients diagnosed between January 2008 and March 2020. Clinicopathologic features and outcomes were reviewed retrospectively. Five cases were tested for BRAF V600 mutations with real-time polymerase chain reaction, and one case was tested with nextgeneration sequencing. Survival was calculated using the Kaplan-Meier method.Results: Thirty-one patients had a mean initial age of 58.32 years (median, 61 years; range 25 to 78 years). There were 13 male and 18 female patients. The median follow-up time was 43.5 months (range, 6 to 155 months) for conjunctival melanoma and 35 months (range, 8 to 151 months) for uveal melanoma. When this study ended, eight of the 12 conjunctival melanoma patients (66.7%) and nine of the 19 uveal melanoma patients (47.4%) had died. The presence of tumor-infiltrating lymphocytes was related to improved overall survival in conjunctival melanoma (p = .014), whereas the presence of ulceration (p = .030), lymphovascular invasion (p = .051), tumor in the left eye (p = .012), tumor thickness of > 2 mm (p = .012), and mitotic count of >1/mm² (p = .012) reduced the overall survival in conjunctival melanoma. Uveal melanoma tumors with the largest diameter of 9.1–15 mm led to the lowest overall survival among subgroups (p = .035). Involvement of the conjunctiva (p=.005) and lens (p = .003) diminished overall survival in uveal melanoma. BRAF V600 mutation was present in one case of conjunctival melanoma, GNAQ R183Q mutation was present in one case of uveal melanoma. Patients with uveal melanoma presented with an advanced pathological tumor stage compared to those with conjunctival melanoma (p = .019).Conclusions: This study confirmed the presence of tumor-infiltrating lymphocytes as a favorable factor in conjunctival melanoma and conjunctival and lens involvement as unfavorable prognostic factors in uveal melanoma for overall survival, respectively.
Abstract
Background: We aimed to determine the effect of clinicopathologic features on overall survival among Caucasian ocular melanoma patients in the Central Anatolia region of Turkey.Methods: This single-center study included conjunctival (n = 12) and uveal (n = 19) melanoma patients diagnosed between January 2008 and March 2020. Clinicopathologic features and outcomes were reviewed retrospectively. Five cases were tested for BRAF V600 mutations with real-time polymerase chain reaction, and one case was tested with nextgeneration sequencing. Survival was calculated using the Kaplan-Meier method.Results: Thirty-one patients had a mean initial age of 58.32 years (median, 61 years; range 25 to 78 years). There were 13 male and 18 female patients. The median follow-up time was 43.5 months (range, 6 to 155 months) for conjunctival melanoma and 35 months (range, 8 to 151 months) for uveal melanoma. When this study ended, eight of the 12 conjunctival melanoma patients (66.7%) and nine of the 19 uveal melanoma patients (47.4%) had died. The presence of tumor-infiltrating lymphocytes was related to improved overall survival in conjunctival melanoma (p = .014), whereas the presence of ulceration (p = .030), lymphovascular invasion (p = .051), tumor in the left eye (p = .012), tumor thickness of > 2 mm (p = .012), and mitotic count of >1/mm² (p = .012) reduced the overall survival in conjunctival melanoma. Uveal melanoma tumors with the largest diameter of 9.1–15 mm led to the lowest overall survival among subgroups (p = .035). Involvement of the conjunctiva (p=.005) and lens (p = .003) diminished overall survival in uveal melanoma. BRAF V600 mutation was present in one case of conjunctival melanoma, GNAQ R183Q mutation was present in one case of uveal melanoma. Patients with uveal melanoma presented with an advanced pathological tumor stage compared to those with conjunctival melanoma (p = .019).Conclusions: This study confirmed the presence of tumor-infiltrating lymphocytes as a favorable factor in conjunctival melanoma and conjunctival and lens involvement as unfavorable prognostic factors in uveal melanoma for overall survival, respectively.
참고문헌 (45)
- Elder DE, "WHO classification of skin tumours" (2018), IARC Press
- Singh AD, "Uveal melanoma : trends in incidence, treatment, and survival", Ophthalmology, 118, pp.1881~1885 (2011)
- Kastelan S, "Conjunctival melanoma : epidemiological trends and features", Pathol Oncol Res, 24, pp.787~796 (2018)
- Kastelan S, "Immunotherapy for uveal melanoma : current knowledge and perspectives", Curr Med Chem, 27, pp.1350~1366 (2020)
- Shields CL, "Prognosis of uveal melanoma based on race in 8100 patients: The 2015 Doyne Lecture", Eye (Lond), 29, pp.1027~1035 (2015)
- Jovanovic P, "Ocular melanoma : an overview of the current status", Int J Clin Exp Pathol, 6, pp.1230~1244 (2013)
- Li Y, "Conjunctival melanoma : update on management", Int Ophthalmol Clin, 59, pp.27~35 (2019)
- Yu GP, "Conjunctival melanoma : is it increasing in the United States?", Am J Ophthalmol, 135, pp.800~806 (2003)
- Vora GK, "Advances in the management of conjunctival melanoma", Surv Ophthalmol, 62, pp.26~42 (2017)
- Tan LLY, "Clinical features and survival outcomes of ocular melanoma in a multi-ethnic Asian cohort", Sci Rep, 10, pp.16367~ (2020)
- Jain P, "Multicenter, international assessment of the eighth edition of the American Joint Committee on Cancer cancer staging manual for conjunctival melanoma", JAMA Ophthalmol, 137, pp.905~911 (2019)
- Sagiv O, "Immunotherapy with programmed cell death 1 inhibitors for 5 patients with conjunctival melanoma", JAMA Ophthalmol, 136, pp.1236~1241 (2018)
- Kaliki S, "Uveal melanoma : relatively rare but deadly cancer", Eye(Lond), 31, pp.241~257 (2017)
- Amin MB, "AJCC cancer staging manual" (2017), Springer
- Esmaeli B, "Histologic features of conjunctival melanoma predictive of metastasis and death(an American Ophthalmological thesis)", Trans Am Ophthalmol Soc, 110, pp.64~73 (2012)
- "Protocol for the examination of specimens from patients with uveal melanoma" (2017)[URL]
- Jager MJ, "Uveal melanoma", Nat Rev Dis Primers, 6, pp.24~ (2020)
- Shields CL, "Diffuse choroidal melanoma : clinical features predictive of metastasis", Arch Ophthalmol, 114, pp.956~963 (1996)
- McLean IW, "Modifications of Callender’s classification of uveal melanoma at the Armed Forces Institute of Pathology", Am J Ophthalmol, 96, pp.502~509 (1983)
- Koc I, "Current management of conjunctival melanoma part 1 : clinical features, diagnosis and histopathology", Turk J Ophthalmol, 50, pp.293~303 (2020)
- Berta-Antalics AI, "Pathology and prognostic factors of conjunctival melanoma", Ophthalmologe, 112, pp.894~898 (2015)
- Wolf J, "Transcriptional characterization of conjunctival melanoma identifies the cellular tumor microenvironment and prognostic gene signatures", Sci Rep, 10, pp.17022~ (2020)
- Tarlan B, "Uveal melanoma : current trends in diagnosis and management", Turk J Ophthalmol, 46, pp.123~137 (2016)
- Kujala E, "Very long-term prognosis of patients with malignant uveal melanoma", Invest Ophthalmol Vis Sci, 44, pp.4651~4659 (2003)
- Alkatan HM, "Enucleated globes with choroidal melanoma : a retrospective histopathological study and correlation with cytogenetic profile in 2 eye centers", Ann Med Surg(Lond), 55, pp.227~233 (2020)
- Shields CL, "Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8, 033 cases", Retina, 32, pp.1363~1372 (2012)
- Kaliki S, "Influence of age on prognosis of young patients with uveal melanoma : a matched retrospective cohort study", Eur J Ophthalmol, 23, pp.208~216 (2013)
- Esmaeli B, "Greater tumor thickness, ulceration, and positive sentinel lymph node are associated with worse prognosis in patients with conjunctival melanoma : implications for future AJCC classifications", Am J Surg Pathol, 43, pp.1701~1710 (2019)
- Tuomaala S, "Prognostic significance of histopathology of primary conjunctival melanoma in Caucasians", Curr Eye Res, 32, pp.939~952 (2007)
- Damato B, "A reappraisal of the significance of largest basal diameter of posterior uveal melanoma", Eye(Lond), 23, pp.2152~2160 (2009)
- Kaliki S, "Uveal melanoma : estimating prognosis", Indian J Ophthalmol, 63, pp.93~102 (2015)
- Cao J, "PD-L1", PD-1 expression and tumor-infiltrating lymphocytes in conjunctival melanoma, 2017, pp.8, 54722~54734
- Anastassiou G, "Expression of cell adhesion molecules and tumour infiltrating leucocytes in conjunctival melanoma", Melanoma Res, 14, pp.381~385 (2004)
- Brouwer NJ, "Conjunctival melanoma : New insights in tumour genetics and immunology, leading to new therapeutic options", Prog Retin Eye Res, 86, pp.100971~ (2022)
- Crawford JB, "Conjunctival melanomas : prognostic factors a review and an analysis of a series", Trans Am Ophthalmol Soc, 78, pp.467~502 (1980)
- Folberg R, "Malignant melanoma of the conjunctiva", Hum Pathol, 16, pp.136~143 (1985)
- Bobic-Radovanovic A, "Predictors of survival in malignant melanoma of the conjunctiva : a clinico-pathological and follow-up study", Eur J Ophthalmol, 8, pp.4~7 (1998)
- Vodencarevic AN, "Epidemiological analysis of ocular melanoma in university clinic center in Tuzla, Bosnia and Herzegovina", Mater Sociomed, 28, pp.314~315 (2016)
- Papastefanou VP, "Uveal melanoma", J Skin Cancer, 2011, pp.573974~ (2011)
- Demirci H, "Ring melanoma of the ciliary body : report on twenty-three patients", Retina, 22, pp.698~706 (2002)
- Shildkrot Y, "Conjunctival melanoma : pitfalls and dilemmas in management", Curr Opin Ophthalmol, 21, pp.380~386 (2010)
- Missotten GS, "Conjunctival melanoma in the Netherlands : a nationwide study", Invest Ophthalmol Vis Sci, 46, pp.75~82 (2005)
- Ortega MA, "Update on uveal melanoma : translational research from biology to clinical practice(Review)", Int J Oncol, 57, pp.1262~1279 (2020)
- Toomey CB, "GNAQ and PMS1 mutations associated with uveal melanoma, ocular surface melanosis, and nevus of ota", Ocul Oncol Pathol, 5, pp.267~272 (2019)
- Rodriguez A, "Clinical presentation and management of uveal melanoma", Mol Clin Oncol, 5, pp.675~677 (2016)